arginylproline: first & second amino acid in substance P sequence; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Arg-Pro : A dipeptide obtained by formal condensation of the carboxy group of L-arginine with the amino group of L-proline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 151003 |
| CHEMBL ID | 48223 |
| CHEBI ID | 141419 |
| SCHEMBL ID | 1674799 |
| MeSH ID | M0117892 |
| Synonym |
|---|
| bdbm50049715 |
| arginylproline |
| CHEMBL48223 , |
| (2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid |
| rp dipeptide |
| arginine proline dipeptide |
| (2s)-1-[(2s)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid |
| l-arginyl-l-proline |
| l-proline, 1-l-arginyl- |
| r-p dipeptide |
| 2418-69-1 |
| arg-pro |
| arginine-proline |
| arginine-proline dipeptide |
| CHEBI:141419 |
| h-arg-pro-oh |
| SCHEMBL1674799 |
| DTXSID70178886 |
| AKOS030622984 |
| arginyl-proline |
| h-arg-pro-oh sulfate salt |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1183271 | Inhibition of ACE (unknown origin) | 2014 | European journal of medicinal chemistry, Sep-12, Volume: 84 | CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.68) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (11.11%) | 0.25% |
| Other | 6 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||